Redeye provides a research update following the Q1 report published by Lipum earlier today. While the company reported a quarterly OPEX above our estimates, the quarter was primarily characterized by the positive phase I study results with SOL-116. The finalized Clinical Study Report further validated earlier topline results, reinforcing our positive outlook on the candidate’s clinical potential.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/